


EA Pharma Co., Ltd.

Company Overview

EA Pharma Co., Ltd. at a Glance

1 Japan's Leading GI Specialty Pharma



We have a wide range of solutions in the field of Gastrointestinal (GI) disease. We hold **the top market share in intestinal cleansers and laxatives***. We cover **a wide range of hospitals and clinics in Japan**.

*In the market for drugs for chronic constipation with a new mechanism of action.

2 FULL Function and Proven R&D



EA Pharma Co., Ltd.
Fukushima Plant

We have our own laboratory, plant and sales branches, and **cover the entire process**. Our R&D is proven, we have **consistently introduced multiple new drugs** into Japanese market.

3 FINANCIAL / FY2023 Revenue

JPY 56.6 Bil.
(USD 391 Mil.)


EA Pharma Co., Ltd. is a subsidiary of Eisai and contributes **29% of the Japan's revenue of Eisai group**. We finance internally through partnerships and thus do not require external fundraising.

4 human health care (hhc) Company



We give **first thought to patients and their families**, striving to enhance the benefits that healthcare offers and meet diverse healthcare needs. We call this **"human health care (hhc)"**.


Corporate Outline



Company name:	EA Pharma Co., Ltd.
Date of establishment:	April 1, 2016
President & CEO:	Hidenori Yabune
Capital:	JPY 9.1 bil. (USD 63 mil.)
Number of employees:	Approx. 910 (as of April 1, 2024) R&D: Approx. 130 Sales & Marketing: Approx. 350
Major shareholders:	Eisai Co., Ltd. 60% Ajinomoto Co., Inc. 40%
Scope of business:	Research and development, manufacturing, sales, import / export of pharmaceuticals and medical devices

Gastrointestinal (GI) Business history


- ✓ EA Pharma Co., Ltd. was established by integrating the Eisai Group's GI disease business, which had been built up over 60 years, and the Ajinomoto Group's GI disease business, which was centered around amino acid technologies.



Revenues by Segment in FY2023

Eisai Group Revenue

JPY 741.8 bil.
(USD 5.1 bil.)



Japan Business

EA Pharma Co., Ltd.

29%


JPY 56.6 Billion
(USD 391 mil.)

JPY 194.3 bil.
(USD 1.3 bil.)

71%
Eisai Japan

Main Commercial Products

Line-up						Main Covered Departments						
Liver	LIVACT®	HEPAN ED®				Gastroenterology	Internal medicine	Psychiatry	Pediatrics			
	Hypoalbuminemia in liver cirrhosis	Hepatic encephalopathy in chronic hepatic disorder										
IBD	ELENTAL®	Nanopia® LRG	RECTABUL®	Jyseleca®	CAROGRA®							
	Improved nutritional status	In vitro diagnostic drugs	Ulcerative colitis	Ulcerative colitis	Ulcerative colitis							
GI Function / Symptom	Pariet®	Selbex®	MOVIPREP®	GOOFICE®	MOVICOL®							
	Peptic ulcer	Gastritis and gastric ulcer	Bowel-cleansing agent	Chronic constipation	Chronic constipation							

 in-licensed products in Japan.

* Register trademark symbol (®) is used for trademarks registered in Japan.
“MOVIPREP” and “MOVICOL” are registered trademarks of the Norgine group.

Development Pipeline

Therapeutic Area	Code	Indication	Pre	P1	P2	P3	NDA
GI Function / Symptom	AJG555	Chronic constipation in children under 2 years of age (Additional Dosage and Administration)					
IBD	AJM347	IBD ($\alpha 4\beta 7$ integrin antagonist)					
	EA1080	IBD ($\alpha 4\beta 7$ integrin antagonist)					
Liver	EA3571	MASH (Enteropeptidase/Trypsin dual inhibitor)					
Neuropathy	EA4017	Chemotherapy-induced peripheral neuropathy					


As of May 15, 2024

Proven R&D and Regulatory in GI

✓ EA Pharma Co., Ltd. has built an impressive track record in R&D and Regulatory functions since its inception.

Clinical Development

✓ Our development team has constantly managed multiple clinical trials.




Regulatory

✓ We have successfully obtained approvals for **4** new drugs in Japan.

Product name	Application category	Approval date	NHI drug price listing date
RECTABUL®	drugs with a new administration route	September 27, 2017	November 22, 2017
GOOFICE®	drugs containing new active ingredients	January 19, 2018	April 18, 2018
MOVICOL®	new ethical combination drugs	September 21, 2018	November 20, 2018
CAROGRA®	drugs containing new active ingredients	March 28, 2022	May 25, 2022

✓ We have actively engaged in conducting clinical studies, not only on our products but also on various diseases, generating robust evidence that maximizes the value of our products.

Medical Affairs



Our Partnering Strategy

In-licensing

- ✓ **We are actively exploring in-licensing opportunities in Japanese market for assets that address unmet medical needs.**
- ✓ **Our scope ranges from early development-stage to commercial-stage products, encompassing not only pharmaceuticals but also medical devices, including digital therapeutics.**

Core therapeutic area

IBD (CD & UC), Liver & pancreas diseases, GI Function / Symptom including chronic constipation and IBS

Strategic therapeutic area

Aimed at Beyond GI, the assets targeting psychiatry and pediatrics are also in our scope.

- ✓ **We are capable of flexibly arranging partnership schemes based on a diverse range of experiences to maximize the project's value.**

Out-licensing

- ✓ **We are actively pursuing out-licensing opportunities to bring our GI products to the global market through partnerships.**

Core therapeutic area

IBD (CD & UC), Liver diseases

EAファーマ株式会社ニーズ

テーマ	説明
医療機器/デジタルヘルスケア/デジタルメディスン	腸の運動・腸に関連したバイオマーカーをモニターするような機器/ソフトウェア、その他消化器疾患の管理、治療を目的とした機器/ソフトウェア
腸内細菌に関連した研究テーマ開発品、技術	モダリティ(FMT、LBP、Phage、Postbiotics、Parabiotics、ペプチド、低分子等)は問われないが、P2試験以降が望ましい、P1試験でも可。モダリティは問われない。 疾患領域は問われないが、消化器疾患、小児疾患、神経疾患、自閉症などの行動症候群、がん領域（既存の抗がん剤との併用も可）が望ましい。
腸のセンシング機能に着目した創薬、腸管選択的な薬剤を用いた創薬	モダリティは問われないが、P2試験以降が望ましい、P1試験でも可。モダリティは問われない。 疾患領域は問われないが、消化器疾患、小児疾患、神経疾患、自閉症などの行動症候群、がん領域（既存の抗がん剤との併用も可）が望ましい。
膵臓疾患に関連した開発品	モダリティは問われないが、P2試験以降が望ましい、P1試験でも可。モダリティは問われない。
ドラックリポジショニング	AI等を用いたドラックリポジショニング技術。Wetでも可。